|
Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer Clinical research trials and Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer. Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer clinical trial. Test subjects typically receive the most expert healthcare available for their Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer  Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer
Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer
For Condition: Carcinoma, Non-Small-Cell Lung
Status: Recruiting
Sponsor(s): OSI Pharmaceuticals ,
Synopsis: The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.
Details: Only patients with 0 to 1 performance status on the ECOG scale are eligible.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer (histological or cytological). - Received prior chemotherapy treatment for advanced, metastatic non-small cell lung cancer. - Measurable disease per RECIST criteria. - Adequate bone marrow, hepatic, and renal function. Exclusion Criteria: - Breast cancer or skin cancer at any time in the past or any other cancer in the past 5 years. - Brain metastases that are unstable, require steroids, are life-threatening, or required radiation in the last 28 days. - Known hypersensitivity to minocycline. - History of serious cardiac disease that is not controlled. - Serious eye conditions. - Prior treatment with inhibitors of EGFR of any kind.
Total Enrollment: 50
Location and Contact Information:
CTRC Institute for Drug Development *Recruiting*
San Antonio, Texas, 78229
United States
Recruiting OSIP Information 800-572-1932
Additional Information:
Study ID Numbers: OSI-774-202; Dose to Rash
Study Start Date: August 2003
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00072631
Other Carcinoma, Non-Small-Cell Lung Studies:
1. A Phase 2 Trial of Antisense Nucleotide to PKC-alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients with Advanced, Previously Untreated Non-Small Cell Lung Cancer.
2. Trial of Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer in Previously Treated Patients
3. Iressa Expanded Access Program (EAP)
4. A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
5. Mistletoe Extract and Gemcitabine for the Treatment of Solid Tumor Cancers
Related Studies:
Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other Texas Clinical Trials
Other San Antonio Clinical Trials
Erlotinib in Treating Patients with Advanced Non-Small Cell Lung Cancer
|
|
|
|
|
|
|
|
